Corcept Therapeutics Incorporated (CORT) has a MoatMap StockRank of 24/100 based on Quality (75/100), Value (21/100), and Momentum (18/100) factor scores. The current signal is SELL. Corcept Therapeutics, a small-cap biotech company, represents a high-risk, binary investment typically outside the fund's quality compounder philosophy. Its success is highly dependent on clinical trials and regulatory approvals, which do not align with predictable cash flows or deep moats, and it carries a 'STRONG_SELL' signal.